Tilray CEO: Opportunities in clinical cannabis are substantial

Tilray CEO: Opportunities in clinical cannabis are substantial

Tilray’s stock is up as of late, nonetheless level-headed down 80 percent from a February high. CNBC’s Frank Holland reports on his dialog with Tilray CEO Irwin Simon about the…